News 2023-09-28
The Pharma Crystallization Summit (PCS) is held annually to bring together developers of new medicines with crystallization challenges and the crystallization experts (solution providers) in the industry and academia.
The Pharma Crystallization Summit (PCS) is held annually to bring together developers of new medicines with crystallization challenges and the crystallization experts (solution providers) in the industry and academia. PCS programs are designed to stimulate in-depth discussions on common and/or leading bottleneck issues related to crystallization of drug substance (DS) as well as the intermediates, the technologies and solutions that are available or underdevelopment. The discussions help new medicine developers to make educated and phase-appropriate decisions, and crystallization experts to understand better the critical needs for providing effective solutions.
The Pharma Crystallization Summit (PCS) has been serving effectively for bridging the gap between drug substance (DS) and drug product (DP) developments. PCS 2023 will be held on October 5 – 6 at New Jersey Institute of Technology (NJIT), Newark, NJ, USA. Extending from the valued topics in the past, this 4th PCS will focus on the following topics:
Session I: Enabling Greener DS Synthetics Routes
Session II: Enabling Desired DS Quality Attributes
Session III: Enabling Improved DP Performance
Panel Discussion Topics:
1) Crystallization challenges and dream solutions supporting synthetic route optimization
2) API isolation challenges and better solutions to ensure robust production
3) Addressing formulation challenges via particle engineering and co-processing
End of Summit & See you in 2024!
Others
More
News 2025-03-21
Porton's Near-Term Target Validated by the SBTi
March 20, 2025, Chongqing—Porton Pharma Solutions Ltd. (Porton) announced today that its near-term greenhouse gas emissions reductions targets have been formally validated by the Science Based Targets initiative (SBTi). This milestone not only signifies its strategic breakthrough in climate governance, but also demonstrates that its decarbonization roadmap is aligned with the 1.5°C climate mitigation pathway.
News 2025-03-19
Porton Advanced Announces Collaboration with Eureka Therapeutics to Accelerate T Cell Therapy Development
Cranbury, New Jersey, March 19, 2025 — Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Eureka Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing novel T‑cell therapies for both solid tumors and hematologic malignancies.
